A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma

This study is testing a combination of two cancer drugs — fruquintinib (a blood vessel growth blocker) and envafolimab (an immunotherapy checkpoint inhibitor) — for people with advanced or locally advanced bone and soft tissue sarcomas that have stopped responding to standard treatments. **You may be eligible if...** - You are between 12 and 70 years old - You have advanced or locally unresectable bone or soft tissue sarcoma confirmed by biopsy - Your cancer has progressed after at least one line of standard treatment - You are in good enough health to participate (adequate organ function) **You may NOT be eligible if...** - You have not received any prior treatment for your sarcoma - You have certain subtypes of sarcoma that are excluded (such as gastrointestinal stromal tumors or Kaposi's sarcoma) - You have serious active infections, heart conditions, or organ dysfunction - You have received prior treatment with these specific drugs or similar agents Talk to your doctor to see if this trial is right for you.